Aandeel ATNM ACTINIUM PHARMACEUTICALS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Actinium Pharmaceuticals, Inc.

Aandelen

ATNM

US00507W2061

Beurs gesloten - Nyse
Andere beurzen
 22:00:00 26-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
6,87 USD +4,73% Intraday-grafiek van Actinium Pharmaceuticals, Inc. +0,29% +35,24%
26/04 Actinium Pharmaceuticals, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024 CI
18/04 Actinium Pharmaceuticals, Inc. Benadrukt het vermogen van Iomab-B om de TP53-mutatie met hoog risico te overwinnen, wat resulteert in een aanzienlijke verbetering van de totale overleving bij patiënten met actief recidief refractaire AML tijdens de European Bone Marrow Transplant Annual Meeting CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML
Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation
InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations
Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy
InvestorBrandMedia: FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"
InvestorBrandMedia: Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge
InvestorBrandMedia: Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings, Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting and Exposition
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ATNM
  4. Nieuws Actinium Pharmaceuticals, Inc.
  5. Andere talen